JHLT: The Podcast
Returning for a second study this month, the JHLT Digital Media Editors invite first author Charlotte Van Edom to discuss the paper, “.” As a cardiologist in training and a PhD candidate at the University Hospitals Leuven in Belgium, Van Edom’s work focuses on hemocompatibility and mechanical circulatory support, covering both short-term and long-term support. The episode explores: The evolution of the use and understanding of direct oral anticoagulants (DOACs) during LVAD support, including the increased focus on Factor Xa inhibitors Encouraging findings from the study and what...
info_outlineJHLT: The Podcast
On this episode of JHLT: The Podcast, the Digital Media Editors invite author Ioana Preston, MD, to discuss the paper, “.” Dr. Preston is the director of the pulmonary hypertension center at Lahey Hospital and Medical Center in Burlington, Massachusetts, and has over 20 years of experience in caring for patients with PH, as well as multiple clinical trials in PH. The episode explores: What makes sotatercept unique as the first “biologic” in the treatment of PAH Hypotheses about the mechanism of action in sotatercept Sotatercept’s interaction with mPAP and what it...
info_outlineJHLT: The Podcast
Returning for a second study this month, the JHLT Digital Media Editors conduct an internal discussion on the paper, “.” The episode explores: The aging PAH population and the new comorbidities that must be considered in research How the study augments and expands on recent standards, like the 2022 ESC/ERS guidelines for pulmonary hypertension Limitations on the study and opportunities for future research For the latest studies from JHLT, visit , or, if you’re an ISHLT member, access your Journal membership at . Those on lung transplant teams should check the previous...
info_outlineJHLT: The Podcast
On this episode of JHLT: The Podcast, the Digital Media Editors invite lead author Jan Van Slambrouck, MD, to discuss the paper, “.” Dr. Van Slambrouck is a general surgeon who’s just finished his PhD training at the KU Leuven lab of respiratory disease and thoracic surgery in Belgium. The episode explores: How rewarming ischemia time (RIT) affects donor lungs, especially on the molecular level The pace of rewarming and how prior literature prepared the team to track and evaluate it Clinical strategies to reduce RIT and directly address molecular changes For...
info_outlineJHLT: The Podcast
Returning for a second study this month, the JHLT Digital Media Editors invite lead author Oliver J.F. Weiner, to discuss the paper, “.” Dr. Weiner is currently an out of training registrar at Monash Health in Melbourne, Australia, but will soon return to his home of the UK to begin internal medicine training with the intention becoming a cardiologist. He is especially interested in advanced heart failure and electrophysiology. The episode explores: The uncertainty around clinical influences on reinnervation The importance of this single-center study in expanding the literature Potential...
info_outlineJHLT: The Podcast
On this episode of JHLT: The Podcast, the Digital Media Editors invite lead author Jonathan E. Williams, MD, to discuss the paper, “.” Dr. Williams is a general surgery resident at the University of Michigan in Ann Arbor, with work focusing on contemporary lung preservation strategies, perfusion techniques, and particularly, EVLP. The episode explores: How the study explores the theory that EVLP use may increase transplant volumes Preserving data quality and other study limitations How to work in fields of study that sometimes yield as many questions as answers For the latest studies...
info_outlineJHLT: The Podcast
JHLT: The Podcast returns with a year-end recap of 2024. Each Digital Media Editor shares one of their favorite studies from JHLT in 2024 for a quick recap of last year’s excellent science in advanced heart and lung disease. Studies featured: · Kikano, Sandra et al. JHLT May 2024 5(43):745-754 · Rose, Johnie et al. JHLT Aug 2024 8(43):1326-1335. · Schlöglhofer, Thomas et al. JHLT Feb 2024 2(43):251-260. ...
info_outlineJHLT: The Podcast
Happy new year from JHLT: The Podcast! On this episode, the Digital Media Editors are joined by ISHLT Director of Marketing + Communications Jess Burke, CAE, to share a little bit about themselves and their backgrounds. Hear about how each of the JHLT Digital Media Editors got involved in transplantation and a little about each of their research and personal interests. For the latest studies from JHLT, visit , or, if you’re an ISHLT member, access your Journal membership at . Don’t already get the Journal? Join the International Society of Heart and Lung Transplantation...
info_outlineJHLT: The Podcast
On the second December episode of JHLT: The Podcast, the Digital Media Editors explore another paper from the December issue of JHLT, entitled “.” First author Entela Bollano, MD, PhD, and senior author Niklas Bergh, MD, PhD, both from the Sahlgrenska University Hospital in Sweden, join the podcast to discuss their work. You’ll hear about: Past outcomes of the SCHEDULE trial, including reduced CAV in patients on everolimus over patients on CNIs How this study filled the need for long-term follow up on randomized studies on immunosuppression Limitations of the study, and what additional...
info_outlineJHLT: The Podcast
On this episode of JHLT: The Podcast, the Digital Media Editors invite lead author Chung-Wai Chow, MD, PhD, FRCPC, to discuss the paper, “.” Dr. Chow is a transplant pulmonologist and clinician scientist at the University of Toronto, with work focusing on investigating air pollution’s impact on chronic lung diseases and developing improved methods to assess lung function. The episode explores: Measurement methods for home and personal air pollution exposures Specific pollutants like black carbon and their effects on patients after lung transplant Practical advice for mitigating these...
info_outlineIn our final episode of 2023, the JHLT Digital Media Editors have two manuscripts from the December 2023 issue of The Journal of Heart and Lung Transplantation! Digital Media Editor Erika Lease, MD, transplant pulmonologist at the University of Washington in Seattle, hosts this episode.
First, a free-ranging conversation with first author Mark E. Snyder, MD, and senior author John F. McDyer, MD, on their team’s study “Impact of age and telomere length on circulating T cells and rejection risk after lung transplantation for idiopathic pulmonary fibrosis.”
A subset of patients with idiopathic pulmonary fibrosis (IPF) have a heritable, age-adjusted short telomere length. Mutations in telomere length can manifest as T-cell dysfunction and immunodeficiency. As T-cells are involved in the development of acute cellular rejection (ACR), the authors hypothesized that the combination of age and telomere length would impact the degree of ACR burden in lung transplant recipients—and indeed, the authors found that lung transplant recipients with IPF and short telomere length had premature “aging” of their circulating T-Cells. There was a significant decline in early ACR burden with increasing age, found only in those with short telomere length.
How might these findings impact immunosuppression regimens in clinical practice? What follow-up studies to they have planned? In the discussion, Drs. Snyder and McDyer, both of UPMC in Pittsburgh, discuss all these possibilities, as well as the the work of their collaborator, Jonathan K. Alder, PhD, as inspiration for the study.
Next, the editors explored “Early optical coherence tomography evaluation of donor-transmitted atherosclerosis and cardiac allograft vasculopathy: insights from a prospective, single-center study,” in a discussion with senior author Snehal R. Patel, MD, of the Montefiore Medical Center in New York.
Cardiac allograft vasculopathy (CAV) remains a major cause of death in heart transplant recipients, and donor-transmitted atherosclerosis (defined as a maximal intimal thickness of >/= 0.5mm on baseline intravascular ultrasound (IVUS) early after transplant) is believed to carry a greater risk for the development of CAV. Dr. Patel’s team, however, hypothesized that optical coherence tomography (OCT) may have advantages over IVUS as an imaging modality due to its higher resolution. In this prospective, observational study, the authors assessed the prognostic role of OCT, and found that transplant recipients whose OCT imaging showed advanced plaque characteristics had a significantly higher event rate after a mean follow up of 3.3 years. OCT was also an independent predictor of clinic events, while maximal intimal thickness of >/= 0.5mm was not.
In the episode, Dr. Patel shares the key features of OCT that may make it of clinical use, the three risk categories developed for the study, and what the follow-ups might be.
Follow along at www.jhltonline.org/current, or, if you’re an ISHLT member, log in at ishlt.org/journal-of-heart-lung-transplantation. Don’t already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.